Table 1. Study & patient characteristics.
| Author (year) | Country | Study design | Sample size change in VA (total population per study) | NF1 nNF1, registered in total study population | Age started CT: mean/median (SD/range) (years) | Time interval (median/range) VA started CT–final VA (years) | (M)DC stage | Definition of change in VA | VA ↑ binoc: N (%) | VA ↔: binoc: N (%) | VA ↓: binoc: N(%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Massimino et al. (2002) [17] | Italy | Prospective, multicenter | 22 (34) | 8/ 26a | 3.2 (0.3–15.6) | 3.7 (0.8–10) | 2 | No definition | 10 (45) | 7 (32) | 5 (23) |
| Dalla Via et al. (2007) [42] | Italy | Prospective, monocenter | 11 (20) | 20 NF1 | 2.2 (1.1–4.2)b | 6.3 (0.4–18)c | 1, 2, 3 | No definition | 0 (0) | 2 (18) | 9 (82) |
| Massimino et al (2010) [43] | Italy | Prospective, center: NEP | 17 (37) | 7/ 30a | 6.0 (0.5–16.5)a | End of CT cycle | 1, 3 | No definition | 7 (41) | 10 (59) | 0 (0) |
| Shofty et al. (2011) [45] | Israel | Retrospective, multicenter | 19 (19) | 11/ 8 | 5.2 (1–9.4) | 4.2 (0.3–11) | 2, 3, 4 | No definition | 1 (5) | 4 (21) | 14 (74) |
| Fisher et al. (2012) [40] | USA, UK, Australia, Canada | Retrospective, multicenter | 88 (115) | 88 NF1 | 4.0 (0.5–16.2) | 3 months after completion of CT cycle | 1, 2, 3, 4 | ≤ = ≥ 0.2 Snellen lines | 28 (32) | 35 (40) | 25 (28) |
| Kalin-Hadju et al. (2014) [31] | Canada | Retrospective, monocenter | 14 (17) | 10/ 7a | 3.4 (3.2–6.6) | 8.2 (3.5–12.9) | 1, 2, 3, 4 | Change per (WHO) category of CVI scale | 1 (7) | 7 (50) | 6 (43) |
| Dodgshun et al. (2015) [9] | Australia | Retrospective, monocenter | 35 (104) | 33/ 71a | 4.6 (0.4–12) | At cessation of CT/ (6.5 (ND)D | 1, 2, 3, 4 | Change in ICO category (13) | 5 (14) | 27 (77) | 3 (9) |
| Prada et al. (2015) [44] | USA | Retrospective, monocenter | 22 (826) | 22 NF1 | 4 (1.8–12) | Not registered | 1, 2, 3, 4 | No definition | 4 (17) | 6 (27) | 12 (56) |
| Doganis et al. (2016) [36] | Greece | Retrospective, monocenter | 16 (20) | 15/5a | 5.3 (1.5–11.4) | End of CT cycle/ 5.2 (2.8–9.4)D | 1, 2, 3 | No definition | 7 (44) | 7 (44) | 2 (12) |
| Lassaletta et al. (2016) [18] | Canada | Prospective, multicenter | 24 (54) | 13/ 41a | 8 (0.7–17.2) | 5 yr (ND) | 2, 3, 4 | No definition | 5 (21) | 15 (62) | 4 (17) |
| Falzon et al. (2018) [29] | UK | Prospective, multicenter | 90 (90) | 46/ 44 | 3.8 (0.8–14) NF1, 3.2 (0.4–15) nNF1 | 6.5 (2.0–10.2) | 1, 2, 3 | ≤ = ≥ 0.2 LogMAR | 19 (21) | 35 (39) | 36 (40) |
| Total | 358 (1,336) | 178/52 |
Abbreviations: CVI: Childhood Visual Impairment; CT: chemotherapy; FU: follow-up; ND: no data; NEP: no extraction possible; NF1: neurofibromatosis type 1; nNF1: no systemic association with neurofibromatosis type 1; (M)DC: (Modified) Dodge Classification; SD: standard deviation; TX: treatment, VA: visual acuity.
*: monocular
a: results only available from total population of study
b: age at diagnosis, age at start of tx not available
c: interval age at diagnosis–final VA
D: long-term data available, change in VA not registered in this table. See Table 3.